Gilternib 40 mg (Gilteritinib Fumarate) Tablets

Gilternib (Gilteritinib) 40 mg Tablets is a targeted anticancer medicine used to treat adults with FLT3 mutation-positive relapsed or refractory Acute Myeloid Leukemia (AML). It works by blocking abnormal FLT3 signaling pathways that promote the growth and survival of leukemia cells. By inhibiting these pathways, Gilteritinib helps slow disease progression and supports better disease control in eligible patients.

Therapeutic Effects

• Treatment of FLT3 mutation-positive relapsed or refractory Acute Myeloid Leukemia (AML)
• Inhibits abnormal FLT3 receptor signaling involved in leukemia cell growth
• Helps reduce the multiplication of leukemia cells
• Supports targeted treatment with less impact on healthy cells compared with conventional chemotherapy
• Used under the supervision of an experienced oncology specialist

Active Ingredient:

• Gilteritinib 40 mg

Dosage Form:

• Film-Coated Tablet

Composition:
Each film-coated tablet contains Gilteritinib 40 mg as the active pharmaceutical ingredient along with pharmaceutical-grade inactive excipients that help ensure tablet stability, absorption, and quality.

The dosage of Gilternib (Gilteritinib) 40 mg Tablets should always be determined by a qualified healthcare professional based on the patient's medical condition, laboratory results, and treatment response.

General Administration Guidelines

• The recommended adult dose is 120 mg once daily (three 40 mg tablets) or as prescribed by the treating oncologist.
• Swallow the tablets whole with water; do not crush, chew, or split them.
• Can be taken with or without food.
• Take the medicine at the same time each day to maintain consistent drug levels.
• If a dose is missed, take it as soon as remembered on the same day. If it is close to the next scheduled dose, skip the missed dose and continue the regular schedule.
• Do not take a double dose to make up for a missed dose.
• Continue treatment only under regular medical supervision, including blood tests and other monitoring as advised by your healthcare provider.

Important: This medicine should be used only under the guidance of an oncology specialist. Do not start, stop, or change the dose without medical advice.